EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
6 clinical trials · Condition
◉ Watch EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
| Record | Firm | Date |
|---|---|---|
| Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma (NCT05202782) | Northwestern University | 2022-03-21 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (NCT04799275) | National Cancer Institute (NCI) | 2021-05-20 |
| Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma (NCT04231877) | University of Washington | 2020-10-27 |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (NCT03984448) | National Cancer Institute (NCI) | 2019-10-22 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (NCT03038672) | National Cancer Institute (NCI) | 2018-12-21 |
Track EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified automatically
Every clearance here is in the API, with alerts when new ones post.